ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

EVG Evgen Pharma Plc

0.80
0.00 (0.00%)
22 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.80 0.75 0.85 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 422k -4.04M -0.0147 -0.51 2.06M
Evgen Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 0.80p. Over the last year, Evgen Pharma shares have traded in a share price range of 0.75p to 3.95p.

Evgen Pharma currently has 274,888,117 shares in issue. The market capitalisation of Evgen Pharma is £2.06 million. Evgen Pharma has a price to earnings ratio (PE ratio) of -0.51.

Evgen Pharma Share Discussion Threads

Showing 11501 to 11525 of 13025 messages
Chat Pages: Latest  461  460  459  458  457  456  455  454  453  452  451  450  Older
DateSubjectAuthorDiscuss
28/2/2023
15:13
A couple more of those and watch the scramble for stock under 4p.
clocktower
28/2/2023
15:09
Well theres a nice 88k buy...keep them coming
markth126
28/2/2023
15:04
I should have added, that we know from history that unlike most AIM companies - news does not leak and PI's are in the same boat as all investors, as there has never been a question I have noticed about insider trading in this and the company directors made that very clear before, so i do not expect the share price to spike wildly before more news but because the share price has drifted one can expect a natural bounce at some point..
clocktower
28/2/2023
14:56
I have watched the trading very closely for some time, and have noticed all the way down until Monday that the difference between buyers and sellers has not been huge - there has been a decent amount of small support much in the same way as today. The only drop of 300k was on Monday I think and bar that the drift has been like a leaking tap in the main.

It may just require a couple of decent buys of 100k to get it moving imo unless another bigger seller turns up but as you say marklth126 - Most big holders are keeping the shares close to their chest.

Still as I said if it drops to the level suggested the other day, I have made funds available, even though I am top heavy already in this but I have total conviction that we will see a substantial increase in the share price and more positive news in the pipeline.

clocktower
28/2/2023
14:14
The big holders are keeping the cards and shares close to their chest, the MM's are picking up weak holder share holders for half price at best. I'm here to watch the story explode throught 23/24
markth126
28/2/2023
13:40
Good find, clocktower. I remain mystified at the share price action here, given all the known knowns alone, but this is AIM. Default fear that something nasty is known by a select few which explains it. Hopefully not, but while no guarantee of and in itself, this is why significant inside buying is so important to small caps, especially at this stage of proceedings. Good, sustained PR/marketing too, which is another thing missing here. Yes, I am a bit fed up. No, I am not selling either :)
lovewinshatelosses
28/2/2023
11:46
I just happened to notice while researching another company, that is was Pinsent Masons that acted for Evgen with the deal with Stalicla rather than just the directors striking up the deal. Hopefully, they are looking at other possible partners on behalf of the company.



"Evgen Pharma Plc
Successfully acted for Evgen Pharma Plc, a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, who have completed a $160 million licensing deal for the global rights of lead asset, SFX-01, in neurodevelopmental disorders and schizophrenia to Stalicla SA.

2022
$160m
United Kingdom and Switzerland"

clocktower
27/2/2023
16:16
You may yet get your 2.85p the way this is going today if there is no news Kingalf, much to my disappointment along with many others I suspect.

Although top heavy I have now made funds available to increase my stake if it should hit that level.

clocktower
27/2/2023
14:32
What is amazing is that you have the likes of CIZ buzzing along and nothing like the Stalicla deal in the bottom drawer it seems, though there are positives there also.
clocktower
27/2/2023
14:19
I think the eagle will have landed before it sinks that low Kingalf, and they genie will show itself before very long.
clocktower
27/2/2023
13:01
Rather than cashing out at 5.89p it now seems more likely that I'll be topping up at 2.85p.
kingalf
27/2/2023
12:39
Price now below Stalicla news deal lol. It's so oversold its untrue. Luckily for me I will be topping up very soon.
wololol
27/2/2023
09:53
Let's get rubbing in that case! GLA.
lovewinshatelosses
27/2/2023
09:05
Hope you all have had a good weekend.

Someone soon will let the genie out of the lamp, and very shortly, I believe, and wishes will be granted when summoned, lovewinshatelosses. :-)

clocktower
24/2/2023
18:28
We can but hope, clocktower. I have said it before, but if the directors were going to buy, they would have done so already at some point. The comms/marketing stuff remains weak too IMO, but consistent with how they operate. So basically, we need a regular flow of positive news to give the share price a floor that is a good deal higher than where we are. Quite simply, most people here are already as loaded as they are willing to be, so we need fresh investors. News is due fairly soon and always the possibility of some new, unexpected, developments as we had with the RNS before the last one.
lovewinshatelosses
24/2/2023
16:12
A couple more folks nibbling away before close, I notice.

Hopefully, next week will bring more positivity back into the stock.

clocktower
24/2/2023
11:19
Sub 4p seems have brought out a couple of bottom fishers today but still very little volume, and as you say peverill, some concrete news or a buy out which I can only envisage one company being interested at this point in time but director buying would also be nice to see if they can now buy but obviously if they are close to another deal being signed they are still locked out.
clocktower
23/2/2023
13:59
Here till we see something concrete or another signing.Or a buyout ;-)
peverill
23/2/2023
12:31
Not even the bottom fishers are interested this week it seems, and bearing in mind the visible spread is now narrow, one would have though a few more would have been attracted.

Still no new deals or any sign of directors buying either.

clocktower
21/2/2023
11:59
Good to see you back and ready to buy W, as you must be one of the few holders on this thread that are not already top heavy on this this stock.

I was looking back on the trades and there were a string of buys over the past 10 days that were showing as sells on ADVFN at around 4.07/8 that were clearly buys - even 150k buy - but now it seems the MM are happy to start walking it up as they are now selling at 4.12p.

If there are a few more buys you might get the signal your waiting for but you might be paying 4.3p I guess but still very cheap indeed.

clocktower
21/2/2023
11:41
A few more buys and I've got my 100k ready. Just waiting for the signal then should get back to 5.5p by end of week.
wololol
21/2/2023
11:16
Only a few bottom fishers seem to interested I notice, has everyone turned their attention to other pharma stocks like DEST, who's stock has been rising slowly up until today.
clocktower
21/2/2023
09:50
It would be good to have a more detailed update from EVG about the progress being made in respect of the agreement with Juvenescence about the milestone payments at the very least:

"Juvenescence Announces Licensing Agreement with Evgen Pharma PLC
September 15, 2020

Juvenescence Limited, a life sciences company focused on modifying aging and increasing human healthspan, announced today a partnership with Evgen Pharma PLC to license its sulforaphane stabilization technology for use in several non-pharmaceutical applications led by its JuvLife division. JuvLife will deploy Evgen’s Sulforadex® stabilization technology to create and manufacture a nutritional health supplement containing a defined and stable dose of sulforaphane, derived from natural sources.

Juvenescence is based on a new understanding of the underlying biological causes of aging, creating evidence-based and science-backed therapies. It is focused on increasing how long people live in health by preventing the diseases of aging in the first place. JuvLife, one of several divisions within Juvenescence, is committed to be the trusted source of scientifically proven, branded health supplements and medical foods that help increase human healthspan and overall quality of life. The Juvenescence team includes highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in the pharmaceutical and consumer health sectors.

Colin Watts, Chief Executive Officer of JuvLife, said: “We are pleased to reach an agreement with Evgen to leverage their scientific technology and expertise to create a differentiated and innovative new product for the global consumer nutritional health market. Sulforaphane is a well-studied natural metabolite derived from cruciferous vegetables that has been shown to activate NRF2 and act as a powerful inducer of the native antioxidant response, helping the body scavenge toxic metabolites and reducing markers of inflammation. In this agreement, we are licensing Evgen’s proprietary technology for the natural extraction and stabilization of sulforaphane in a potent and cost-advantaged form that we believe is superior to all other sources currently commercially available. Juvenescence has built a reputation as a broad-based healthcare company in the longevity space through strong partnerships with scientific leaders in their specific areas and we are delighted to have such a partner in Evgen.’’

The license is for exclusive rights to leverage certain patents and know-how for all non-pharmaceutical applications in the United States, with options for the other major markets namely, Europe, Asia and Rest of World. Evgen will receive upfront and milestone payments of up to $10.5m, and in addition, royalties on sales of the commercialized product."

clocktower
21/2/2023
08:53
Timbo003 - even if folks watch the last 7 mins of that programme they might find the information valuable as to how we look and understand others that have all sorts of different experiences or limitations, and how intelligent they maybe regardless of appearances.

Turning back to EVG - all very stagnant over the past 10 days or so.

clocktower
17/2/2023
06:20
Well worth a watch over the weekend

Chris Packham:
Inside Our Autistic Minds

timbo003
Chat Pages: Latest  461  460  459  458  457  456  455  454  453  452  451  450  Older